{"id":68188,"date":"2026-06-15T20:43:05","date_gmt":"2026-06-15T12:43:05","guid":{"rendered":"https:\/\/flcube.com\/?p=68188"},"modified":"2026-06-15T20:43:06","modified_gmt":"2026-06-15T12:43:06","slug":"merck-secures-fda-approval-for-keytruda-welireg-combination-as-adjuvant-therapy-in-high-risk-kidney-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68188","title":{"rendered":"Merck Secures FDA Approval for Keytruda-Welireg Combination as Adjuvant Therapy in High-Risk Kidney Cancer"},"content":{"rendered":"\n

Merck & Co., Inc. (MSD; NYSE: MRK<\/a>)<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved Keytruda (pembrolizumab)<\/strong> and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)<\/strong>, each in combination with Merck’s first-in-class oral hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) inhibitor Welireg (belzutifan)<\/strong>, as adjuvant treatment<\/strong> for adult patients with clear cell renal cell carcinoma (ccRCC)<\/strong> who are at intermediate-high or high risk of recurrence<\/strong> following nephrectomy, or following nephrectomy and resection of metastatic lesions.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>FDA (United States)<\/td><\/tr>
Approval Type<\/strong><\/td>Full approval<\/td><\/tr>
Products<\/strong><\/td>Keytruda + Welireg combination therapy<\/td><\/tr>
Indication<\/strong><\/td>Adjuvant treatment of ccRCC at intermediate-high\/high risk of recurrence<\/td><\/tr>
Patient Population<\/strong><\/td>Post-nephrectomy patients with or without metastatic lesion resection<\/td><\/tr>
Approval Basis<\/strong><\/td>Phase 3 LITESPARK-022 trial results<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Trial Results \u2013 LITESPARK-022<\/h2>\n\n\n\n
Endpoint<\/th>Keytruda + Welireg<\/th>Keytruda + Placebo<\/th>Hazard Ratio (95% CI)<\/th>p-value<\/th><\/tr><\/thead>
Disease-Free Survival (DFS)<\/strong><\/td>Primary endpoint met<\/td>Comparator arm<\/td>HR=0.72 [0.59-0.87]<\/td>0.0003<\/td><\/tr>
Risk Reduction<\/strong><\/td>28% reduction in disease recurrence, metastasis, or death<\/td>\u2014<\/td>\u2014<\/td>\u2014<\/td><\/tr>
24-month DFS Rate<\/strong><\/td>81% [0.78-0.83]<\/td>74% [0.71-0.77]<\/td>\u2014<\/td>\u2014<\/td><\/tr>
Median DFS<\/strong><\/td>Not reached<\/td>Not reached<\/td>\u2014<\/td>\u2014<\/td><\/tr>
Overall Survival<\/strong><\/td>Not mature (interim analysis)<\/td>Not mature<\/td>\u2014<\/td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Trial Design Highlights<\/h3>\n\n\n\n